Antiglaucoma drugs for achieving monovision after laser in situ keratomileusis

We report on a patient in whom the use of antiglaucoma drugs has been beneficial for the attainment of monovision after laser in situ keratomileusis (LASIK). A 57-year-old woman undergoing LASIK complained of blurred vision in the right eye. After a successful trial of monovision with contact lenses, antiglaucoma drugs (2.5% nipradilol) were administered topically to the right eye twice a day to establish monovision. In the right eye, the manifest refraction was changed from -4.0, -1.0 x 80, with an uncorrected visual acuity (UCVA) of 0.3 for near vision before treatment, to -2.5, -1.0 x 80, with an UCVA of 0.9 for near vision after treatment, while, in the left eye, it was 0, -1.0 x 100, with an UCVA of 0.9 for far vision. Binocular UCVA was improved from 0.3 for near and 0.9 for distance vision before treatment, to 0.9 for near and 1.0 for distance vision after treatment. No complications were observed and the manifest refraction remained stable during the 6-month follow-up period. The use of antiglaucoma drugs may be helpful for the achievement of monovision by reduction of myopic regression after LASIK.